Meyyappan Muthuppalaniappan

This inventor holds 32 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Kinase Modulators. Top assignees: Rhizen Pharmaceuticals Sa, Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals Ag. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Meyyappan Muthuppalaniappan. Retrieved from https://idiyas.com/inventor/meyyappan-muthuppalaniappan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 32 (Patent Applications = 6)

% Patents Active = 46.9

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 120(Granted Patents)

Company Filing History:

31 out of 51

Rhizen Pharmaceuticals Sa

patents

5 out of 7

Incozen Therapeutics Pvt. Ltd.

patents

1 out of 5

Rhizen Pharmaceuticals Ag

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

Areas of Expertise:

Kinase Modulators

Selective PI3K Delta Inhibitors

Calcium Release-Activated Calcium Channel

Immunomodulator Compounds

3H-Imidazo Compounds

Chromene Compounds

Anti-Inflammatory Compounds

Triazolo Compounds

Protein Kinases

Non-Small Cell Lung Cancer

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858907 - Kinase modulators (2024-01-02),

2. 11066402 - 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases (2021-07-20),

3. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases (2021-06-01),

4. 10981919 - Selective PI3K delta inhibitors (2021-04-20),

5. 10668051 - Modulators of calcium release-activated calcium channel (2020-06-02),

6. 10590129 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2020-03-17),

7. 10570142 - Selective PI3K delta inhibitors (2020-02-25),

8. 10538501 - Kinase modulators (2020-01-21),

9. 10442783 - 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases (2019-10-15),

10. 10322130 - Substituted chromenones as modulators of protein kinases (2019-06-18),

11. 10246450 - Modulators of calcium release-activated calcium channel (2019-04-02),

12. 10220035 - Compounds as modulators of protein kinases (2019-03-05),

13. 10174034 - Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer (2019-01-08),

14. 10087182 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2018-10-02),

15. 10072013 - Selective PI3K delta inhibitors (2018-09-11),

Title: Meyyappan Muthuppalaniappan: A Pioneer in Kinase Modulator Innovations

Introduction

Meyyappan Muthuppalaniappan is an accomplished inventor based in Hyderabad, Telangana, India. With a remarkable portfolio of 32 patents, he has made significant contributions to the field of biochemistry, particularly in the development of kinase modulators. His innovative work has paved the way for new therapeutic treatments in a variety of kinase-mediated diseases.

Latest Patents

One of Muthuppalaniappan's recent inventions focuses on PI3K protein kinase modulators, presenting compounds of Formula (I). These modulators offer methods of preparation, pharmaceutical compositions, and effective treatment options for diseases influenced by kinase activity. Additionally, he has developed 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B]pyridine compounds that serve as modulators of c-Met protein kinases. His work includes comprehensive methods of preparation and treatment for disorders linked to c-Met kinase activity.

Career Highlights

Throughout his career, Meyyappan Muthuppalaniappan has collaborated with notable organizations, including Rhizen Pharmaceuticals and Incozen Therapeutics Private Limited. His experience in these companies has contributed to the advancement of therapeutic solutions and highlighted his expertise in the biotechnology sector.

Collaborations

Muthuppalaniappan has worked alongside esteemed colleagues such as Srikant Viswanadha and Govindarajulu Babu. These collaborations reflect a shared commitment to innovation and a dedication to scientific research, which has been instrumental in the success of their collective endeavors.

Conclusion

Meyyappan Muthuppalaniappan's extensive work in the field of kinase modulators underscores his role as a leading inventor and innovator. With a solid foundation in research and development, his patents not only contribute to scientific knowledge but also open new avenues for therapeutic interventions. As he continues to make strides in biochemistry, the impact of his innovations will undoubtedly be felt for years to come.

Profile summary based on public USPTO records.